These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26715490)

  • 1. Pattern, Determinants, and Impact of HIV Spending on Care and Treatment in 38 High-Burden Low- and Middle-Income Countries.
    Granich R; Gupta S; Montaner J; Williams B; Zuniga JM
    J Int Assoc Provid AIDS Care; 2016; 15(2):91-100. PubMed ID: 26715490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995-2015.
    Global Burden of Disease Health Financing Collaborator Network
    Lancet; 2018 May; 391(10132):1799-1829. PubMed ID: 29678342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for additional government spending on HIV/AIDS in 137 low-income and middle-income countries: an economic modelling study.
    Haakenstad A; Moses MW; Tao T; Tsakalos G; Zlavog B; Kates J; Wexler A; Murray CJL; Dieleman JL
    Lancet HIV; 2019 Jun; 6(6):e382-e395. PubMed ID: 31036482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of High Out of Pocket Spending for HIV Care Leading to Catastrophic Expenditure for Affected Patients in Lao People's Democratic Republic.
    Barennes H; Frichittavong A; Gripenberg M; Koffi P
    PLoS One; 2015; 10(9):e0136664. PubMed ID: 26327558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of government HIV/AIDS financing: a 10-year trend analysis from 125 low- and middle-income countries.
    Ávila C; Loncar D; Amico P; De Lay P
    BMC Public Health; 2013 Jul; 13():673. PubMed ID: 23870494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health.
    Beck EJ; Passarelli C; Lui I; Guichard AC; Simao M; De Lay P; Loures L
    Antivir Ther; 2014; 19 Suppl 3():117-23. PubMed ID: 25310477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Funding AIDS programmes in the era of shared responsibility: an analysis of domestic spending in 12 low-income and middle-income countries.
    Resch S; Ryckman T; Hecht R
    Lancet Glob Health; 2015 Jan; 3(1):e52-61. PubMed ID: 25539970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost implications of HIV retesting for verification in Africa.
    Lasry A; Kalou MB; Young PR; Rurangirwa J; Parekh B; Behel S
    PLoS One; 2019; 14(7):e0218936. PubMed ID: 31260467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
    Quentin W; König HH; Schmidt JO; Kalk A
    Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When to start antiretroviral therapy in adults in low- and middle-income countries: science and practice.
    Munderi P
    Curr Opin HIV AIDS; 2010 Jan; 5(1):6-11. PubMed ID: 20046142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human resources for treating HIV/AIDS: needs, capacities, and gaps.
    Bärnighausen T; Bloom DE; Humair S
    AIDS Patient Care STDS; 2007 Nov; 21(11):799-812. PubMed ID: 17944556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technical efficiency of national HIV/AIDS spending in 78 countries between 2010 and 2018: A data envelopment analysis.
    Allel K; Abou Jaoude GJ; Birungi C; Palmer T; Skordis J; Haghparast-Bidgoli H
    PLOS Glob Public Health; 2022; 2(8):e0000463. PubMed ID: 36962380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV drug resistance in low-income and middle-income countries.
    Hamers RL; Rinke de Wit TF; Holmes CB
    Lancet HIV; 2018 Oct; 5(10):e588-e596. PubMed ID: 30193863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV.
    Snider JT; Goldman DP; Rosenblatt L; Seekins D; Juday T; Sanchez Y; Wu Y; Peneva D; Romley JA
    Med Care Res Rev; 2016 Jun; 73(3):329-48. PubMed ID: 26537525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using information on ART costs and benefits to mobilise resources - comparing different methods and contexts.
    Kinghorn A
    Afr J AIDS Res; 2019 Dec; 18(4):289-296. PubMed ID: 31779574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How can earlier entry of patients into antiretroviral programs in low-income countries be promoted?
    Lawn SD; Wood R
    Clin Infect Dis; 2006 Feb; 42(3):431-2; author reply 432-3. PubMed ID: 16392093
    [No Abstract]   [Full Text] [Related]  

  • 18. Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31.
    Hecht R; Stover J; Bollinger L; Muhib F; Case K; de Ferranti D
    Lancet; 2010 Oct; 376(9748):1254-60. PubMed ID: 20934597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to optimize HIV treatment outcomes in resource-limited settings.
    Nakanjako D; Colebunders R; Coutinho AG; Kamya MR
    AIDS Rev; 2009; 11(4):179-89. PubMed ID: 19940945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Financing the HIV response in sub-Saharan Africa from domestic sources: Moving beyond a normative approach.
    Remme M; Siapka M; Sterck O; Ncube M; Watts C; Vassall A
    Soc Sci Med; 2016 Nov; 169():66-76. PubMed ID: 27693973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.